title: Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema.
abstract: OBJECTIVE
  To estimate health status utility (preference) weights for hereditary angioedema (HAE) during an attack and between attacks using data from the Hereditary Angioedema Burden of Illness Study in Europe (HAE-BOIS-Europe) survey. Utility measures quantitatively describe the net impact of a condition on a patient's life; a score of 0.0 reflects death and 1.0 reflects full health.
  
  
  METHODS
  The HAE-BOIS-Europe was a cross-sectional survey conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE from the patient perspective. Survey items that overlapped conceptually with the EuroQol 5-Dimensions (EQ-5D) domains (pain/discomfort, mobility, self-care, usual activities, and anxiety/depression) were manually crosswalked to the corresponding UK population-based EQ-5D utility weights. EQ-5D utilities were computed for each respondent in the HAE-BOIS-Europe survey for acute attacks and between attacks.
  
  
  RESULTS
  Overall, a total of 111 HAE-BOIS-Europe participants completed all selected survey items and thus allowed for computation of EQ-5D-based utilities. The mean utilities for an HAE attack and between attacks were 0.44 and 0.72, respectively. Utilities for an acute attack were dependent on the severity of pain of the last attack (0.61 for no pain or mild pain, 0.47 for moderate pain, and 0.08 for severe pain). There were no significant differences across countries. Mean utilities derived from the study approach compare sensibly with other disease states for both acute attacks and between attacks.
  
  
  CONCLUSIONS
  The impacts of HAE translate into substantial health status disutilities associated with acute attacks as well as between attacks, documenting that the detrimental effects of HAE are meaningful from the patient perspective. Results were consistent across countries with regard to pain severity and in comparison to similar disease states. The results can be used to raise awareness of HAE as a serious disease with wide-ranging personal and social impacts.
authors.affiliation: Angioedema Centre, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
authors.forename: Emel
authors.initials: E
authors.lastname: Aygören-Pürsün
authors.affiliation: Hereditary Angioedema Centre Denmark, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.
authors.forename: Anette
authors.initials: A
authors.lastname: Bygum
authors.affiliation: Outcomes Research Strategies in Health, Washington, DC.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Beusterien
authors.affiliation: Patient Reported Outcomes, Oxford Outcomes Inc., an ICON plc company, Bethesda, MD, USA.
authors.forename: Emily
authors.initials: E
authors.lastname: Hautamaki
authors.affiliation: ViroPharma Incorporated, Chatsworth House, Maidenhead, UK.
authors.forename: Zlatko
authors.initials: Z
authors.lastname: Sisic
authors.affiliation: HAEi - Hereditary Angioedema International Patient Organization for C1 Inhibitor Deficiencies, Skanderborg, Denmark.
authors.forename: Henrik B
authors.initials: HB
authors.lastname: Boysen
authors.affiliation: Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases U754 (CIBERER), University Hospital La Paz, Madrid, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Caballero
keywords: EQ-5D; burden of illness; health-related quality of life; hereditary angioedema